The pharmaceutical company Pfizer has signed an agreement with the US government to provide 10 million Paxlovid pills, which is still pending official authorization and aspires to be the first oral treatment against covid-19 in the country.
Under the agreement, the government will pay Pfizer $ 5.29 billion for the ten million treatments once the Food and Drug Administration (FDA) approve the so-called “emergency use authorization” of the drug and delivery will begin at the end of this year and continue throughout 2022.
The agreement signed with the government is reached two weeks after Pfizer released the pill results with 90% effectiveness for high-risk patients who accumulated three days of covid-19 symptoms. The agreed price has taken into account the principles of “commitment, volume, equity and affordability,” the company said in a statement.
In parallel, Pfizer is negotiating bilaterally with regulatory agencies to conclude similar agreements with a hundred countries around the world to distribute the Paxlovid.
Pfizer is positioned as one of the pharmaceutical companies that has gone the furthest in the production of oral drugs against COVID-19, together with Merck, which has launched Molnupiravir, approved for the moment in the United Kingdom in early November and with an ongoing negotiation with the FDA.
Mario Twitchell is an accomplished author and journalist, known for his insightful and thought-provoking writing on a wide range of topics including general and opinion. He currently works as a writer at 247 news agency, where he has established himself as a respected voice in the industry.
